• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

937265-83-3 (ARRY-380 (analog ))

1

Identification

ARRY-380 (analog ) ARRY-380 (analog )
Name ARRY-380 (analog )
Formula C29H27N7O4S
MW 569.6342
CAS No. 937265-83-3
EINECS
Smiles O=S(CCNCC1=CC=C(C2=CC3=C(NC4=CC=C(OC5=CC6=NC=NN6C=C5)C(C)=C4)N=CN=C3C=C2)O1)(C)=O
Synonyms
InChI InChI=1S/C29H27N7O4S/c1-19-13-21(4-7-26(19)39-22-9-11-36-28(15-22)32-18-34-36)35-29-24-14-20(3-6-25(24)31-17-33-29)27-8-5-23(40-27)16-30-10-12-41(2,37)38/h3-9,11,13-15,17-18,30H,10,12,16H2,1-2H3,(H,31,33,35)
2

Introduction

Background Information

ARRY-380 is a potent and selective HER2 inhibitor with IC50 of 8 nM, equipotent against truncated p95-HER2, 500-fold more selective for HER2 versus EGFR. ......by BOC Sciences
ARRY-380 is an orally bioavailable inhibitor of the human epidermal growth factor receptor tyrosine kinase ErbB-2 (also called HER2) with potential antineoplastic activity. ErbB-2 inhibitor ARRY-380 selectively binds to and inhibits the phosphorylation of ErbB-2, which may prevent the activation of ErbB-2 signal transduction pathways, resulting in growth inhibition and death of ErbB-2-expressing tumor cells. ErbB-2 is overexpressed in a variety of cancers and plays an important role in cellular proliferation and differentiation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus). Shelf life: >2 years if stored properly Drug formulation: ......by MedKoo Biosciences, Inc.
ARRY-380 is a potent and selective HER2 inhibitor with IC50 of 8 nM, equipotent against truncated p95-HER2, 500-fold more selective for HER2 versus EGFR. Phase 1. ......by Selleck Chemicals LLC
HER2 is a member of the human epidermal growth factor receptor (HER/EGFR/ERBB) family. Amplification or overexpression of this oncogene has been shown to play an important role in the development and progression of certain aggressive types of breast cancer. ARRY-380 is an orally bioavailable inhibitor of the human epidermal growth factor receptor tyrosine kinase ErbB-2 (also called HER2) with potential antineoplastic activity. ......by Target Molecule Corp.
3

Protocol(Only for Reference)

Cell Experiment

Animal Experiment

4

Physical and Chemical Properties

Appearance:White to off-white solid EBNumber:EB000028682

Storage condition

Solubility

DMSO ≥110mg/mL Water <1.2mg/mL Ethanol <1.2mg/mL by MedChemexpress Co., Ltd.
DMSO 114 mg/mL (200 mM) ; Water <1 mg/mL (<1 mM) ; Ethanol <1 mg/mL (<1 mM) by Selleck Chemicals LLC
5

Mechanism and Indication

6

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase
ARRY-380 (analog ) Oncothyreon Inc Metastatic breast cancer 2013/10/31 2015/8/31 Phase 1 Clinical
ARRY-380 (analog ) Dana-Farber Cancer Institute Inc Metastatic breast cancer 2013/8/31 2019/11/30 Phase 1 Clinical
ARRY-380 (analog ) Array BioPharma Inc Advanced solid tumor 2008/5/31 2013/3/31 Phase 1 Clinical
ARRY-380 (analog ) - No Development Reported
7

Safety Data of ARRY-380 (analog )

8

Spectral Information

9

Suppliers List

Company Price and Availability Country/Region
BOC Sciences
Biochempartner Co., Ltd China
CHEMSCENE, LLC 5mg/USD144();10mg/USD228() USA
MedChemexpress Co., Ltd. 5mg/USD144();10mg/USD228() USA
MedKoo Biosciences, Inc. USA
Selleck Chemicals LLC 5mg/USD270(In stock);10mg/USD370(In stock);50mg/USD1070(In stock);200mg/USD2470(In stock) USA
Shanghai Haoyuan Chemexpress Co., Ltd. 5mg/USD144();10mg/USD228() China
Target Molecule Corp. 5mg/USD116();10mg/USD192();25mg/USD358();50mg/USD610() USA
10

Related Products

Other Forms of 937265-83-3

Name CAS No Formula MW

Recommended Compounds in EGFR

Name CAS No Formula MW
Ginsenoside Rh2 78214-33-2 C36H62O8 622.87
Mutated EGFR-IN-1 1421372-66-8 C25H31N7O 445.56
AZD-9291 (mesylate) 1421373-66-1 C29H37N7O5S 595.71
Mutant EGFR inhibitor 1421373-62-7 C27H30ClN7O2 520.03
AZD-9291 1421373-65-0 C28H33N7O2 499.61
WHI-P180 (hydrochloride) 153437-55-9 C16H16ClN3O3 333.77
WHI-P180 211555-08-7 C16H15N3O3 297.31
Gefitinib (hydrochloride) 184475-55-6 C22H25Cl2FN4O3 483.36
Erlotinib (mesylate) 248594-19-6 C23H27N3O7S 489.54
BGB-102 807640-87-5 C22H25BrN4O2 457.36
Poziotinib 1092364-38-9 C23H21Cl2FN4O3 491.34
CO-1686 (hydrobromide) 1446700-26-0 C27H29BrF3N7O3 636.46
CO-1686 1374640-70-6 C27H28F3N7O3 555.55
CNX-2006 1375465-09-0 C26H27F4N7O2 545.53
PD168393 194423-15-9 C17H13BrN4O 369.2153
AG 18 118409-57-7 C10H6N2O2 186.17
Afatinib (dimaleate) 850140-73-7 C32H33ClFN5O11 718.08
Chrysophanol 481-74-3 C15H10O4 254.2375
AG-1478 153436-53-4 C16H14ClN3O2 315.75
Mubritinib 366017-09-6 C25H23F3N4O2 468.47

Recommended Compounds in Same Indication

Name CAS No Formula MW
OSI-930 728033-96-3 C22H16F3N3O2S 443.44
AT7867 857531-00-1 C20H20ClN3 337.85
NVP-BGJ398 872511-34-7 C26H31Cl2N7O3 560.48
BMS-599626 (Hydrochloride) 873837-23-1 C27H28ClFN8O3 567.01
RO4987655 874101-00-5 C20H19F3IN3O5 565.28
MGCD-265 analog 875337-44-3 C26H20FN5O2S2 517.5977
Regorafenib (Hydrochloride) 835621-07-3 C21H16Cl2F4N4O3 519.28
Ostarine 841205-47-8 C19H14F3N3O3 389.33
AT9283 896466-04-9 C19H23N7O2 381.43
KX2-391 897016-82-9 C26H29N3O3 431.53
MLN4924 905579-51-3 C21H25N5O4S 443.52
SNX-2112 908112-43-6 C23H27F3N4O3 464.48
ABC294640 915385-81-8 C23H25ClN2O 380.91
OTSSP167 1431697-89-0 C25H28Cl2N4O2 487.42
MK-0752 471905-41-6 C21H21ClF2O4S 442.9
ZSTK474 475110-96-4 C19H21F2N7O2 417.41
Cyclophosphamide 50-18-0 C7H15Cl2N2O2P 261.09
BMS-599626 714971-09-2 C27H27FN8O3 530.55
Retaspimycin 857402-23-4 C31H45N3O8 587.7
Retaspimycin (Hydrochloride) 857402-63-2 C31H46ClN3O8 624.17
11

Route of Synthesis

12

References

13

More Information

ARRY-380 (analog )

Tags: buy 937265-83-3 IC50 | 937265-83-3 price | 937265-83-3 cost | 937265-83-3 solubility | 937265-83-3 purchase | 937265-83-3 manufacturer | 937265-83-3 research buy | 937265-83-3 order | 937265-83-3 MSDS | 937265-83-3 chemical structure | 937265-83-3 Storage condition | 937265-83-3 molecular weight | 937265-83-3 mw | 937265-83-3 datasheet | 937265-83-3 supplier | 937265-83-3 cell line | 937265-83-3 NMR | 937265-83-3 MS | 937265-83-3 IR | 937265-83-3 solubility | 937265-83-3 Safe information | 937265-83-3 Qc and Spectral Information | 937265-83-3 Clinical Information | 937265-83-3 Clinical Trial | 937265-83-3 Route of Synthesis | 937265-83-3 storage condition | 937265-83-3 diseases and conditions | 937265-83-3 flash point | 937265-83-3 boiling point | 937265-83-3 melting point | 937265-83-3 storage condition | 937265-83-3 brand